Exhibit 99.1 Assertio Reports First Quarter 2024 Financial Results First Quarter Net Product Sales of $31.9 Million Rolvedon Growth Continues, with $14.5 million in Net Product Sales $7.5 Million in Cash Flow from Operations Increases Cash to $80.7 Million LAKE FOREST, IL. – May 6, 2024 – Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for t ...

公司业绩 - Assertio Holdings, Inc.将于2024年5月6日发布第一季度财务业绩[1] 公司活动 - 可通过公司投资者关系网站访问直播网络研讨会和电话会议信息[2] 公司介绍 - Assertio是一家提供差异化产品给患者的商业制药公司[4]

任命新董事 - Assertio Holdings, Inc.宣布任命Sigurd (Sig) Kirk加入董事会，他将加入审计和薪酬委员会[1] - Kirk在制药领域拥有超过20年的经验，曾在Allergan plc和Barr Pharmaceuticals等公司担任高级企业业务发展执行官和财务管理职务[2] - 公司表示Sig Kirk的战略业务发展和财务管理背景将为Assertio带来增长机会，展示了公司对董事会专业知识与业务战略的持续关注[3]

公司活动 - Assertio Holdings, Inc.宣布首席财务官Ajay Patel将在2024年4月9日在纽约举行的LD Micro Invitational XIV Conference上发表演讲[1] - 公司将在东部时间下午4:00举行集体演讲，并全天提供个别会议[2] - 投资者可以通过会议平台请求与公司会面，或通过mkreps@darrowir.com联系Assertio投资者关系[3] - 有关演示信息将在活动当天提供，并可在https://investor.assertiotx.com上访问[4]

财务数据和关键指标变化 - 2023年第四季度总销售额为32.5百万美元,其中Rolvedon销售额为11百万美元,Indocin销售额为10.8百万美元 [19][20] - 毛利率为70%,较上年同期的88%下降,主要是由于库存摊销和销售结构变化 [21] - 经营亏损为32.3百万美元,主要包括4.1百万美元的无形资产减值和1.7百万美元的Indocin或有负债公允价值变动收益 [23] - 调整后EBITDA为4.5百万美元,体现了公司业务模式的韧性 [24] - 2023年末现金73.4百万美元,债务40百万美元 [25] - 2023年第四季度经营活动产生的现金流为5.7百万美元 [25] 各条业务线数据和关键指标变化 - Rolvedon销售额环比增长38%,达到11百万美元,但受渠道库存调整影响 [34][35] - Indocin销售额受到竞争性仿制药进入市场的影响,同比和环比均有下降 [20] 各个市场数据和关键指标变化 - 未提及具体市场数据和关键指标变化 公司战略和发展方向及行业竞争 - 公司将Rolvedon定位为主要增长动力,并优化商业团队以提高其盈利能力 [34][39] - 公司将继续关注Otrexup和Sympazan等其他产品的增长机会,并积极寻求合适的并购机会 [61][64] - 公司将专注于成本效率和现金流生成,同时保持现金流正向 [15][30] 管理层对经营环境和未来前景的评论 - 管理层对Rolvedon的增长前景持乐观态度,预计2024年销售额将接近60百万美元 [26][27] - 管理层预计Indocin销售额将在18-25百万美元区间,受到仿制药竞争的持续不利影响 [27] - 管理层预计2024年总销售额将在110-125百万美元区间,调整后EBITDA在20-30百万美元区间 [26][28] 问答环节重要的提问和回答 问题1 **Thomas Flaten 提问** 询问Rolvedon商业团队的调整情况 [44][45] **Paul Schwichtenberg 回答** 公司将商业团队调整为32人,包括16名实地销售人员,以更好地服务现有客户并拓展新客户 [45][46][49] 问题2 **Jim Sidoti 提问** 询问2024年运营费用指引 [55] **Ajay Patel 回答** 公司预计2024年运营费用在65-70百万美元区间 [56] 问题3 **Jim Sidoti 提问** 询问Rolvedon销售目标是否需要依赖同日给药获批 [57] **Ajay Patel 回答** Rolvedon超过100百万美元销售目标不需要依赖同日给药,如果获批将带来额外的上行空间 [58][59]

Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of $20 to $30 Million LAKE FOREST, Il., March 11, 2024 (GLOBE NEWSWIRE) --  Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the fourth quarter and full year ended D ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39294 ASSERTIO HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 85-0598378 (STATE OR OTHER JURISDICTION OF (I.R.S ...

Exhibit 99.1 Assertio Reports Fourth Quarter and Full Year 2023 Financial Results Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of $20 to $30 Million LAKE FOREST, IL. – March 11, 2024 – Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today report ...

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) and reminds investors of the March 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 ...

If you suffered losses exceeding $25,000 investing in Assertio stock or options between March 9, 2023 and November 8, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/ASRT. There is no cost or obligation to you. NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential ...